The U.S. Food and Drug Administration (FDA) approved Soleno Therapeutics’ drug on Wednesday to treat a rare genetic disorder that causes intense and persistent feelings of hunger. This marks the first approved treatment for patients suffering from this condition, which has long lacked effective therapies.
The disorder, known as Prader-Willi Syndrome (PWS), leads to insatiable hunger, often resulting in obesity and related health complications. The newly approved drug offers hope for improved management of symptoms and quality of life for patients.
Medical experts and patient advocacy groups have praised the approval, as it opens the door for future research and treatments for other rare disorders.
